• Lei Song, Jing Li, Changdong Guan, Quanmin Jing, Shuzheng Lu, Lixia Yang, Kai Xu, Yuejin Yang, Bo Xu, Yaling Han, and I-LOVE-IT 2 Investigators.
• Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases, Beijing, China.
• Catheter Cardiovasc Interv. 2018 Feb 15; 91 (S1): 608-616.

ObjectivesWe aimed to compare the long-term outcomes of the novel biodegradable polymer cobalt-chromium sirolimus-eluting stent (BP-SES) versus the durable polymer sirolimus-eluting stent (DP-SES) in the I-LOVE-IT2 trial.BackgroundsComparisons of the long-term safety and efficiency of the BP-DES versus the DP-DES are limited.MethodsA total of 2,737 patients eligible for coronary stenting were randomized to the BP-SES or DP-SES group at a 2:1 ratio. The primary endpoint of target lesion failure (TLF) was defined as a composite of cardiac death, target vessel myocardial infarction (MI), or clinically indicated target lesion revascularization.ResultsA three-year clinical follow-up period was available for 2,663 (97.3%) patients. There were no significant differences in TLF (8.9% vs. 8.6%, P = 0.81), patient-oriented composite endpoint (PoCE) (15.2% vs.14.5%, P = 0.63), or individual components between the BP-SES and DP-SES. Definite/probable stent thrombosis (ST) was low and similar at 3 years (0.8% vs. 1.0%, P = 0.64). Landmark analysis of 1-3 years showed that the TLF (2.7% vs. 2.6%, P = 0.81), PoCE (6.2% vs. 5.1%, P = 0.28), and definite/probable ST (0.4% vs. 0.4%, P = 1.00) were comparable between the 2 arms.ConclusionsIn this prospective randomized trial, the BP-SES showed similar clinical results versus the DP-SES in terms of safety and efficacy outcomes over a 3-year follow-up period.© 2018 Wiley Periodicals, Inc.

46 keywords...

hide…